Skip to main
LQDA
LQDA logo

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 0%
Sell 13%
Strong Sell 0%

Bulls say

Liquidia Corp, a biopharmaceutical company focusing on treatments for pulmonary hypertension, is poised for potential cash-flow positivity and profitability sooner than expected, bolstered by disciplined spending, improving gross margins, and an efficient specialty-pharmacy model. The company anticipates strong third-quarter performance for its product YUTREPIA, with management reporting sustained referral momentum, increased prescriber adoption, and established broad payer access across major national plans. Early metrics reveal robust adoption, evidenced by approximately 900 referrals and a 75% conversion rate to paid therapy within just 11 weeks, highlighting strong operational performance and market traction.

Bears say

Liquidia Corp faces significant investor anxiety regarding potential competition from sotatercept, which could lead to a diminished market for prostacyclin products, including its flagship offering, YUTREPIA. Additionally, the company is confronted with multiple risks that could negatively impact its revenue projections, including the possibility of failing to meet peak commercial revenue estimates due to factors such as market size, penetration rates, and pricing strategies. Furthermore, concerns about securing sufficient capital resources to support ongoing operations and development, along with competitive pressures in the biopharmaceutical sector, contribute to a negative outlook for Liquidia's stock.

LQDA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 8 analysts, LQDA has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.